Strong growth Medpace is experiencing solid revenue growth in 2026, with nine-month revenue of $2.13B and quarterly revenue of $716M, indicating expanding demand for central lab services in Phase I-IV clinical trials.

Global lab network Operates four wholly-owned labs across the US, Belgium, China, and Singapore, supported by robust specimen management and logistics, signaling opportunities for multinational trials requiring coordinated, standardized central lab data across regions.

IT and QA expansion Active investment in IT talent in India and broad technology stack usage suggests emphasis on data management, validation, and scalable infrastructure, presenting cross-sell potential for enhanced laboratory information systems and QA services.

Industry recognition Recipient of the 2026 CRO SCRS Eagle Award for trusted partnerships with clinical sites, highlighting a competitive differentiator in site collaboration and patient-centric trial delivery that can be leveraged in enterprise-level sales conversations.

Customer base breadth Serves a spectrum from small biotech to large multinational pharma, indicating flexibility and potential for tiered service offerings, from standard central lab panels to customized, integrated solutions for complex late-stage trials.